The emerging science of precision psychiatry – which aims to understand and directly treat the biology behind psychotic disorders such as schizophrenia – lies at the core of Boehringer Ingelheim GmbH’s central nervous system research and development program. Its freshly signed collaboration with the US-based Lieber Institute for Brain Development should advance those efforts, BI’s recently-appointed head of CNS disease R&D Hugh Marston told Scrip.
Boehringer Ingelheim To Focus On Precision Psychiatry In CNS
R&D Mission: Explore Brain’s Biological Circuitry
Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.
More from Business
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.